|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case number** | **Hospital Cluster** | **Gender** | **Ethnicity** | **Age of presentation (years)** | **Antecedent infections** | **Presenting symptom** | **Abnormal (psychiatric) behavior or cognitive dysfunction** | **Speech dysfunction** | **Seizures** | **Movement disorder, dyskinesia, or rigidity / abnormal postures** | **Decreased level of consciousness** | **Autonomic dysfunction or central hypoventilation** |
| **1** | HKW | F | Chinese | 13 | + | Speech dysfunction | + | + | + | - | - | - |
| **2** | HKW | F | Chinese | 13 | + | Seizure | + | - | + | - | + | - |
| **3** | HKW | F | Chinese | 3 | + | Seizure | + | + | + | + | - | - |
| **4** | HKW | F | Caucasian | 3 | + | Abnormal behavior | + | + | + | + | + | - |
| **5** | HKW | F | Chinese | 13 | + | Speech dysfunction | + | + | + | - | - | - |
| **6** | HKW | M | Chinese | 9 | + | Abnormal behavior | + | + | + | + | + | - |
| **7** | HKW | F | Chinese | 1 | + (HSV encephalitis) | Decreased level of consciousness | - | - | + | + | + | - |
| **8** | KE | M | Chinese | 13 | + | Abnormal behavior | + | + | + | + | + | + |
| **9** | KE | F | Chinese | 17 | + | Abnormal behavior | + | + | + | + | + | + |
| **10** | KE | F | Chinese | 12 | + | Abnormal behavior | + | + | + | + | + | + |
| **11** | KC | M | Chinese | 4 | - | Abnormal behavior | + | + | + | + | + | - |
| **12** | KC | M | Chinese | 5 | + | Abnormal behavior | + | + | + | + | + | + |
| **13** | NTE | M | Chinese | 12 | - | Abnormal behavior | + | + | + | + | - | - |
| **14** | NTE | F | Chinese | 5 | + | Speech dysfunction | + | + | - | + | - | - |
| **15** | KW | F | Chinese | 13 | - | Abnormal behavior | + | + | + | + | + | + |

Supplementary Table 1a: Demographics and clinical features of individual patients with anti-NMDAR encephalitis.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Case number** | **CSF anti-NMDAR antibody** | **Serum anti-NMDAR antibody** | **CSF pleocytosis** | **CSF oligoclonal band** | **MRI Brain** | **EEG** | **Tumor** |
| **1** | + | + | + | - | Normal | Electrographical seizure | - |
| **2** | + | - | - | - | Normal | Electrographical seizure | - |
| **3** | + | - | + | - | Normal | Focal slowing | - |
| **4** | + | + | + | + | Non-specific findings (diffuse T2 hyperintensities in white matter) | Generalised slowing | - |
| **5** | + | + | + | - | Non-specific findings (T2 hyperintensities in pons and periaqueductal white matter) | Generalised slowing | - |
| **6** | + | + | - | - | Normal | Normal | - |
| **7** | Not available | + | - | - | Abnormal (diffuse encephalomalacic changes) | Generalised slowing | - |
| **8** | + | - | - | - | Normal | Generalised slowing | - |
| **9** | + | + | + | - | Normal | Generalised slowing | - |
| **10** | + | - | + | - | Normal | Generalised slowing | - |
| **11** | + | + | + | + | Normal | Electrographical seizure | - |
| **12** | + | + | + | - | Normal | Generalised slowing | - |
| **13** | + | + | + | - | Normal | Epileptiform discharge | - |
| **14** | + | - | + | Not available | Normal | Focal slowing | - |
| **15** | Not available | + | + | Not available | Normal | Normal | - |

Supplementary Table 1b: Investigation findings of individual patients with anti-NMDAR encephalitis.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case number** | **Steroid** | **IVIG** | **Plasmapheresis** | **Rituximab** | **ICU stay (days)** | **Hospital stay (excluding ICU stay) (days)** | **Recovery** | **Follow up duration (months)** |
| **1** | + | + | - | - | 0 | 47 | Full | 18 |
| **2** | + | - | - | - | 4 | 26 | Full | 11 |
| **3** | + | + | - | - | 0 | 88 | Full | 11 |
| **4** | + | + | - | - | 7 | 58 | Full | 23 |
| **5** | + | + | - | - | 0 | 44 | Limited (behavioral problems) | 45 |
| **6** | + | + | - | - | 10 | 35 | Full | 36 |
| **7** | + | + | - | - | 0 | 34 | Limited (HSV encephalitis) | 84 |
| **8** | + | + | - | - | 10 | 69 | Full | 48 |
| **9** | + | + | + | + | 18 | 38 | Substantial (mild personality change) | 12 |
| **10** | + | + | + | + | 16 | 85 | Substantial (mild personality change) | 3 |
| **11** | + | + | - | - | 10 | 30 | Full | 12 |
| **12** | + | + | - | - | 6 | 33 (discharge against medical advice) | Not available | Not available |
| **13** | + | + | + | + | 30 | 210 | Full | 48 |
| **14** | - | + | - | - | 0 | 20 | Full | 12 |
| **15** | + | + | - | - | 38 | 13 | Full | 36 |

Supplementary Table 1c: Treatment and outcome of individual patients with anti-NMDAR encephalitis